Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305770 · ClinicalTrials.gov registry record · NA
DD T2 Daily Disposable Registration Trial
A NA study of Myopia and Refractive Errors, sponsored by Alcon Research.
- Completed
- Registry status
- NA
- Development phase
- 107
- Enrollment target
- 6
- Study locations
NCT03305770: Completed NA study of Myopia and Refractive Errors, sponsored by Alcon Research.
NCT03305770 is a NA study of Myopia and Refractive Errors that has completed, run by Alcon Research. The registered enrollment target is 107 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03305770, a NA study of Myopia and Refractive Errors, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 107 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to evaluate the performance of the investigational verofilcon A contact lens compared to the commercially available delefilcon A contact lens, by assessing visual acuity as the primary variable.
Primary Outcome
VA was assessed for each eye individually using a Snellen chart at a distance of 4 meters. A 20/20 Snellen acuity is considered normal distance eyesight. No formal hypotheses were formulated; hence no inferential testing was performed.
Conditions Studied
Interventions
- DEVICE verofilcon A contact lenses
- DEVICE delefilcon A contact lenses
Study Locations (6)
Florida
- Alcon Investigative Site - Longwood
- Alcon Investigative Site - Maitland
Tennessee
- Alcon Investigative Site - Brentwood
- Alcon Investigative Site - Memphis
California
- Alcon Investigative Site - San Diego
Illinois
- Alcon Investigative Site - Bloomington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2018-02-21 |
| Phase | NA |
What the finished NCT03305770 record still lists
NCT03305770 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which verofilcon A contact lenses is the first listed.
NCT03305770 lists 6 locations in 4 states (Florida, Tennessee, California).
Frequently Asked Questions
What is clinical trial NCT03305770 about?
NCT03305770 is a clinical study titled "DD T2 Daily Disposable Registration Trial". The purpose of this study is to evaluate the performance of the investigational verofilcon A contact lens compared to the commercially available delefilcon A contact lens, by assessing visual acuity as the primary variable.
What is the current status of trial NCT03305770?
This trial is currently completed. It is a NA study. The enrollment target is 107 participants. The study started on 2017-10-12. Estimated completion is 2018-02-21.
What conditions does trial NCT03305770 study?
This clinical trial studies the following conditions: Myopia, Refractive Errors.
What interventions are being tested in trial NCT03305770?
The interventions under investigation include: verofilcon A contact lenses (DEVICE), delefilcon A contact lenses (DEVICE).
Who is sponsoring clinical trial NCT03305770?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03305770 being conducted?
This trial has 6 study locations across California, Florida, Illinois, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03305770's enrollment target sits among peer trials
107 39th of 90 higher than 52 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI